1. UK cancer incidence statistics for males, 2003. Cancer Research UK website (http://info.cancerresearchuk.org/cancerstats/incidence/males/?a=5441) February 2007.
2. Royal College of Radiologists Clinical Oncology Information Network & British Association of Urological Surgeons (1999) Guidelines on the management of prostate cancer. Clinical Oncology 11:55–81
3. National Institute for Clinical Excellence (2002) Improving Outcomes in Urological Cancers: The Manual, Published by the National Institute for Clinical Excellence, London
4. McWilliam LJ, Roberts ISD, Davies DR Problems in grading and staging prostatic carcinoma. Current Diagnostic Pthology, 2002 8, 65-75.
5. Kirby RS et al. (2001) Fast Facts; Prostate cancer. Health Press
6. Perez CA et al. (1993) Localised cancer of the prostate (stages T1B, T1C, T2, and T3): Review of management with external beam radiation therapy. Cancer, 72: 3156–3173
7. Pilepich MV, Krall JM, Al-Sarraf M et al. (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostate cancer. A randomised comparative trial of the Radiation Therapy Oncology Group. Urology 45:616–623
8. Henry AM, Price P, Logue JP et al (2004). Controversies in the radiotherapeutic management of poor prognosis locally advanced prostate cancer. Clinical Oncology 16: 87–94.
9. Roach M, Lu J, Lawton C et al. (2002) A phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to total androgen suppression: preliminary analysis of RTOG 9413. ASCO Abstract 7111
10. Zietman AL et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled controlled trial. JAMA 2005;294:1233-9.
11. Zelefsky MJ et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiotherapy & Oncology 2000;55(3):241-9.
12. Pilepich M, Winter K, John M et al (2001). Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. International Journal of Radiation Oncology Biology & Physics 50: 1243–1252
13. Hanks GE, Pajak TF, Porter A et al. (2004) Phase III trial of long-term adjuvant androgen deprivation and neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02, Journal of Clinical Oncology 21: 3972–3978
14. Denham JW, Steigler A, Lamb D.S et al . (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial: the Lancet Oncology 6:841- 850
15. Tyrell CJ, Payne H, See WA et al . (2005) Bicalutamide (Casodex) 150mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme: Radiotherapy and Oncology 76:4-10
16. Medical Research Council Prostate Cancer Working Party Investigators Working Group (1997). Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. British Journal of Urology 79; 235–246.
17. Improving Outcomes in Urological Cancers: The Manual (2002) National Institute for Health and Clinical Excellence (NICE).
18. Royal College of Radiologists Clinical Oncology Information Network (COIN) & British Association of Urological Surgeons (BAUS) Guidelines on the management of prostate cancer. Clinical Oncology 1999; 11:55-81.
19. Parker C, Clarke N, Logue J et al. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery): Clinical Oncology 19:167-171
20. Bonney WW, Schned AR, Timberlake DS (1999) Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end points and meta-analysis of randomized trials. Journal of Urology 160: 1754–1760
21. Prostate cancer: diagnosis and treatment. National Institute for Health and Clinical Excellence (NICE) guidelines (February 2008).